Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

2019150 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Journal of Thoracic Oncology

Volume 14, Issue 6, pp. 1086-1094

Field-Weighted Citation Impact: 14.50